

DAFTAR PUSTAKA

1. Alkabban FM, Ferguson T. Breast Cancer [Internet]. NCBI Bookshelf. 2021 [cited 2022 Sep 11]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482286/>
2. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis.* 2018 Jun 1;5(2):77–106.
3. International Agency for Research on Cancer. Estimated number of incident cases and deaths of Cancer [Internet]. GLOBOCAN. 2020 [cited 2022 Oct 20]. Available from: <https://gco.iarc.fr/today/>
4. Pangribowo S. Infodatin: Beban Kanker di Indonesia. Jakarta: Kementerian Kesehatan RI; 2019.
5. Kementerian Kesehatan Republik Indonesia. Profil Kesehatan Indonesia 2020. Jakarta: Kementerian Kesehatan RI; 2021.
6. He Z, Chen Z, Tan M, Elingarami S, Liu Y, Li T, et al. A review on methods for diagnosis of breast cancer cells and tissues. *Cell Prolif.* 2020 Jul 1;53(7).
7. Shafatujjahan, Ifatujjahan, Biswas RSR. Molecular Subtypes of Breast Cancer Patients According to St Gallen Classification. *Chattogram Maa-O-Shishu Hospital Medical College Journal* [Internet]. 2020;19(1):55–8. Available from: www.banglajol.info/index.php/CMOSHMCJ

8. Vasconcelos I, Hussainzada A, Berger S, Fietze E, Linke J, Siedentopf F, et al. The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival. *Breast*. 2016 Oct 1;29:181–5.
9. Setyawati Y, Rahmawati Y, Widodo I, Ghozali A, Purnomosari D. The association between molecular subtypes of breast cancer with histological grade and lymph node metastases in Indonesian woman. *Asian Pacific Journal of Cancer Prevention*. 2018 May 1;19(5):1263–8.
10. Singh D, Mukherjee S. Impact of Molecular Subtypes of Breast Cancer on Axillary Lymph Node Metastasis: A Tertiary Center Experience. *Archives of Breast Cancer*. 2021 Oct 31;305–12.
11. Wilson BE, Desnoyers A, Al-Showbaki L, Nadler MB, Amir E. A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time. *Sci Rep*. 2022 Dec 1;12(1).
12. van Nguyen C, Tien Nguyen Q, Thi Ngoc Vu H, Hong Pham K, Thi Phung H. Molecular classification predicts survival for breast cancer patients in Vietnam: a single institutional retrospective analysis. *Int J Clin Exp Pathol* [Internet]. 2021;14(3):322–37. Available from: www.ijcep.com/
13. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast cancer prognostic classification in the molecular era: The role of histological grade. *Breast Cancer Research*. 2010 Aug 24;12(4).


14. Wang Y, Acs B, Robertson S, Liu B, Solorzano L, Wählby C, et al. Improved breast cancer histological grading using deep learning. *Annals of Oncology*. 2022 Jan 1;33(1):89–98.
15. Rahman M, Mohammed S. Breast cancer metastasis and the lymphatic system (Review). *Oncol Lett*. 2015 Sep 1;10(3):1233–9.
16. Nathanson SD, Rosso K, Chitale D, Burke M. Lymph Node Metastasis. In: *Introduction to Cancer Metastasis*. Elsevier Inc.; 2016. p. 235–61.
17. Singh D, Mandal A. The prognostic value of lymph node ratio in survival of non-metastatic breast carcinoma patients. *Breast Cancer Res Treat*. 2020 Dec 1;184(3):839–48.
18. Kim H, Park W, Kim SS, Ahn SJ, Kim YB, Kim TH, et al. Prognosis of patients with axillary lymph node metastases from occult breast cancer: Analysis of multicenter data. *Radiat Oncol J*. 2021 Jun 1;39(2):107–12.
19. Łukasiewicz S, Czezelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—An updated review. *Cancers(Basel)*. 2021 Sep 1;13(17).
20. Dinas Kesehatan Provinsi Sumatera Barat. *Profil Dinas Kesehatan tahun 2017*. Padang: Dinkes SUMBAR; 2018.
21. Smolarz B, Zdrożna Nowak A, Romanowicz H. Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). *Cancers (Basel)*. 2022 May 1;14(10).

22. Watkins EJ. Overview of breast cancer. *J Am Acad Physician Assist.* 2019 Oct 1;32(10):13–7.
23. Sobri FB, Azhar Y, Wibisana IGN G, Rachman A. Manajemen terkini kanker payudara. Edisi I. Jakarta: Perhimpunan Ahli Bedah Onkologi Indonesia; 2017.
24. Waks AG, Winer EP. Breast Cancer Treatment: A Review. *JAMA - Journal of the American Medical Association.* 2019 Jan 22;321(3):288–300.
25. Chand P, Anubha G, Singla V, Rani N. Evaluation of immunohistochemical profile of breast cancer for prognostics and therapeutic use. *Nigerian Journal of Surgery.* 2018;24(2):100.
26. Ilić IR, Stojanović NM, Radulović NS, Živković V v., Randjelović PJ, Petrović AS, et al. The quantitative ER immunohistochemical analysis in breast cancer: Detecting the 3 + 0, 4 + 0, and 5 + 0 allred score cases. *Medicina (Lithuania).* 2019 Aug 1;55(8).
27. Kalli S, Semine A, Cohen S, Naber SP, Makim SS, Bahl M. American joint committee on cancer's staging system for breast cancer, eighth edition: What the radiologist needs to know. *Radiographics.* 2018 Nov 1;38(7):1921–33.
28. Perhimpunan Ahli Bedah Onkologi Indonesia. Panduan Penatalaksanaan Kanker 2020. Edisi II. Handono D et al, editor. Jakarta: PERABOI; 2020.
29. Kerr AJ, Dodwell D, McGale P, Holt F, Duane F, Mannu G, et al. Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects

on mortality. Cancer Treat Rev. 2022 Apr 1;105.




30. Tong CWS, Wu M, Cho WCS, To KKW. Recent advances in the treatment of breast cancer. *Front Oncol*. 2018 Jun 14;8.
31. Sugiarto Hadiyanto AV, Miranti IP, Prajoko YW, Istiadi H. Histological and Clinical Stage Profiles of Young-aged Breast Carcinoma. *Diponegoro International Medical Journal*. 2022 Jul 29;3(1):1–6.
32. Zhang X, Yang J, Cai H, Ye Y. Young age is an independent adverse prognostic factor in early stage breast cancer: A population-based study. *Cancer Manag Res*. 2018;10:4005–18.
33. Dai X, et al. Breast cancer intrinsic subtype classification , clinical use and future trends. 2015;2929–43.
34. Anderson KN, Schwab RB, Martinez ME. Reproductive risk factors and breast cancer subtypes: A review of the literature. *Breast Cancer Res Treat*. 2014;144(1):1–10.
35. Barańska A, Dolar-Szczasny J, Kanadys W, Kinik W, Ceglarska D, ReligioniU, et al. Oral Contraceptive Use and Breast Cancer Risk According to Molecular Subtypes Status: A Systematic Review and Meta-Analysis of Case-Control Studies. *Cancers (Basel)*. 2022 Feb 1;14(3).
36. Yucel B, Bahar S, Kacan T, Seker MM, Celasun MG, Bahceci A, et al. Importance of Metastasis Site in Survival of Patients with Breast Cancer. *Austin J Med Oncol* [Internet]. 2014; Available from: www.austinpublishinggroup.com



37. Yazdani A, Dorri S, Atashi A, Shirafkan H, Zabolinezhad H. Bone Metastasis Prognostic Factors in Breast Cancer. *Breast Cancer (Auckl)*. 2019 Feb 1;13.
38. Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. *BMC Cancer*. 2019 Nov 12;19(1).
39. Baqher Hussaini SA, Andola SK, Anita AM. Study of Metastasis in Lymphnode Biopsies with Special Reference to Immunohistochemistry (IHC) in Metastatic Breast Carcinoma. *Journal of Clinical and Diagnostic Research*. 2015 Mar 1;9(3):EC13–6.
40. Yang ZJ, Yu Y, Hou XW, Chi JR, Ge J, Wang X, et al. The prognostic value of node status in different breast cancer subtypes. *Oncotarget* [Internet]. 2017;8(3):4563–71. Available from: www.impactjournals.com/oncotarget/
41. Tonello F, Bergmann A, Abrahao K de S, Sales de Aguiar S, Adeodato Bello M, Santos Thuler LC. Impact of Number of Positive Lymph Nodes and Lymph Node Ratio on Survival of Women with Node-Positive Breast Cancer. *Eur J Breast Health* [Internet]. 2019 Apr 4;15(2):76–84. Available from: http://cms.galenos.com.tr/Uploads/Article_41996/ejbh-15-76-En.pdf
42. van Doornijeweert C, van Diest PJ, Ellis IO. Grading of invasive breast carcinoma: the way forward. *Virchows Archiv*. 2022 Jan 1;480(1):33–43.
43. Patel A, Unni N, Peng Y. The changing paradigm for the treatment of HER2-positive breast cancer. *Cancers (Basel)*. 2020 Aug 1;12(8):1–17.

44. Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. *Cancer Biol Med*. 2016 Dec 1;13(4):496–504.
45. Wu Q, Ma G, Deng Y, Luo W, Zhao Y, Li W, et al. Prognostic value of ki- 67 in patients with resected triple-negative breast cancer: A meta-analysis. *Front Oncol*. 2019;9(OCT).
46. Nguyen D, Yu J, Reinhold WC, Yang SX. Association of Independent Prognostic Factors and Treatment Modality with Survival and Recurrence Outcomes in Breast Cancer. *JAMA Netw Open*. 2020 Jul 9;3(7).
47. de Boniface J, Szulkin R, Johansson ALV. Survival after Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status: A Swedish National 6-Year Follow-up of 48986 Women. *JAMA Surg*. 2021 Jul 1;156(7):628–37.
48. Andring LM, Diao K, Sun S, Patel M, Whitman GJ, Schlembach P, et al. Locoregional Management and Prognostic Factors in Breast Cancer With Ipsilateral Internal Mammary and Axillary Lymph Node Involvement. *International Journal of Radiation Oncology*Biophysics*. 2022 Jul;113(3):552–60.
49. Wei J, Jiang Y, Shao Z. The survival benefit of postmastectomy radiotherapy for breast cancer patients with T1-2N1 disease according to molecular subtype. *Breast*. 2020 Jun 1;51:40–9.
50. Wang J, Xu B. Targeted therapeutic options and future perspectives for her2-positive breast cancer. *Signal Transduct Target Ther*. 2019;4(1).

51. Toss A, Venturelli M, Peterle C, Piacentini F, Cascinu S, Cortesi L. Molecular biomarkers for prediction of targeted therapy response in metastatic breast cancer: Trick or treat? *Int J Mol Sci.* 2017 Jan 4;18(1).
52. Masoud V, Pagès G. Targeted therapies in breast cancer: New challenges to fight against resistance. *World J Clin Oncol.* 2017 Apr 10;8(2):120–34.
53. Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. *J Hematol Oncol.* 2022 Dec 1;15(1).
54. Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, et al. FOXA1 is an independent prognostic marker for ER-positive breast cancer. *Breast Cancer Res Treat.* 2012;131(3):881–90.
55. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, le Quesne J, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. *Br J Cancer.* 2010 Aug 24;103(5):668–75.
56. Gasco M, Shami S, Crook T. Review: The p53 pathway in breast cancer. *Breast Cancer Res.* 2002;4:70–6.
57. Al-thoubaity FK. Molecular classification of breast cancer: A retrospective cohort study. *Annals of Medicine and Surgery.* 2020 Jan 1;49:44–8.
58. Mohammed AA. The clinical behavior of different molecular subtypes of breast cancer. *Cancer Treat Res Commun.* 2021 Jan 1;29.



59. Si C, Jin Y, Wang H, Zou Q. Association between molecular subtypes and lymph node status in invasive breast cancer. *Int J Clin Exp Pathol* [Internet]. 2014;7(10):6800–6. Available from: www.ijcep.com/
60. Rossing M, Pedersen CB, Tvedskov T, Vejborg I, Talman ML, Olsen LR, et al. Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status. *Sci Rep*. 2021 Dec 1;11(1).
61. Min SK, Lee SK, Woo J, Jung SM, Ryu JM, Yu J, et al. Relation between tumor size and lymph node metastasis according to subtypes of breast cancer. *J Breast Cancer*. 2021;24(1):75–84.
62. Sofi GN, Sofi JN, Nadeem R, Shiekh RY, Khan FA, Sofi AA, et al. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. *Asian Pacific Journal of Cancer Prevention*. 2012;13(10):5047–52.
63. Liu N, Yang Z, Liu X, Niu Y. Lymph node status in different molecular subtype of breast cancer: triple negative tumours are more likely lymph node negative. *Oncotarget* [Internet]. 2017;8(33):55534–43. Available from: www.impactjournals.com/oncotarget
64. Ding S, Sun X, Lu S, Wang Z, Chen X, Shen K. Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer. *Breast*. 2021 Jun 1;57:71–9.
65. Zuo T, Zeng H, Li H, Liu S, Yang L, Xia C, et al. The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-


based multi-center study. Chin J Cancer. 2017 Dec;36(1).



66. Aryandono T, Author C. Hormone Receptor Status of Operable Breast Cancers in Indonesia: Correlation with Other Prognostic Factors and Survival. *Hormone Receptor Status and Breast Cancer Survival in Indonesia Asian Pacific J Cancer Prev.* 2006;7:321–4.
67. Schwartz AM, Henson DE, Chen D, Rajamarthandan S. Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: A study of 161 708 cases of breast cancer from the SEER program. *Arch Pathol Lab Med.* 2014;138(8):1048–52.
68. Jaroensri R, Wulczyn E, Hegde N, Brown T, Flament-Auvigne I, Tan F, et al. Deep learning models for histologic grading of breast cancer and association with disease prognosis. *NPJ Breast Cancer.* 2022 Dec 1;8(1).
69. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast cancer prognostic classification in the molecular era: The role of histological grade. *Breast Cancer Research.* 2010 Aug 24;12(4).
70. Urru SAM, Gallus S, Bosetti C, Moi T, Medda R, Sollai E, et al. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. *BMC Cancer.* 2018 Jan 8;18(1).
71. Kim JM, Kim JY, Jung EJ, Kwag SJ, Park JH, Park T, et al. The prognosis factors among breast cancer patients with extensive axillary lymph node metastasis. *Korean Journal of Clinical Oncology.* 2018 Jun 30;14(1):43–7.

72. Tang C, Wang P, Li X, Zhao B, Yang H, Yu H, et al. Lymph node status have a prognostic impact in breast cancer patients with distant metastasis. PLoS One. 2017 Aug 1;12(8).
73. Kim JS, Kim K, Shin KH, Kim JH, Ahn S do, Kim SS, et al. Cervical lymphnode involvement above the supraclavicular fossa in breast cancer: Comparison with stage iic (krog 18-02). J Breast Cancer. 2020 Apr 1;23(2):194–204.
74. Dahlan MS. Analisis Survival Dasar-Dasar Teori dan Aplikasi Program Stata. Jakarta: CV Sagung Seto; 2013.
75. Chen HL, Zhou MQ, Tian W, Meng KX, He HF. Effect of age on breast cancer patient prognoses: A population-based study using the SEER 18 database. PLoS One. 2016 Oct 1;11(10).
76. Dai D, Zhong Y, Wang Z, Yousafzai NA, Jin H, Wang X. The prognostic impact of age in different molecular subtypes of breast cancer: A population-based study. PeerJ. 2019;2019(7).
77. Lee SH, Kim YS, Han W, Ryu HS, Chang JM, Cho N, et al. Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography. Medicine (United States). 2016;95(37).
78. Kim J, Kim JY, Lee HB, Lee YJ, Seong MK, Paik N, et al. Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no special type. Breast Cancer Res Treat. 2020 Nov 1;184(2):527–42.

79. Krishnamurti U, Silverman JF. HER2 in Breast Cancer: A Review and Update. *Adv Anat Patol* [Internet]. 2014;21(2):100–7. Available from: www.anatomicpathology.com
80. el Fatemi H, Chahbouni S, Jayi S, Moumna K, Melhouf MA, Bannani A, et al. Retraction: Luminal B tumors are the most frequent molecular subtype in breast cancer of north african women: An immunohistochemical profile study from morocco. *Diagn Pathol*. 2013 Aug 14;8(1).
81. Paramita S, Raharjo EN, Niasari M, Azizah F, Hanifah NA. Luminal B is the most common intrinsic molecular subtypes of invasive ductal breast carcinoma patients in East Kalimantan, Indonesia. *Asian Pacific Journal of Cancer Prevention*. 2019;20(8):2247–52.
82. Eliyatkin N, Yalcin E, Zengel B, Aktaş S, Vardar E. Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. *Journal of Breast Health*. 2015 Apr 7;11(2):59–66.
83. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. Vol. 5, *World Journal of Clinical Oncology*. Baishideng Publishing Group Co., Limited; 2014. p. 412–24.
84. Hashmi AA, Aijaz S, Khan SM, Mahboob R, Irfan M, Zafar NI, et al. Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. *World J Surg Oncol*. 2018 Jan 2;16(1).
85. Widodo I, Dwianingsih EK, Aryandono T, Soeripto. Clinicopathological characteristic and prognostic significance of Indonesian triple negative



breastcancer. Indonesian Biomedical Journal. 2019;11(3):286–92.



86. Metovic J, Bragoni A, Osella-Abate S, Borella F, Benedetto C, Gualano MR, et al. Clinical Relevance of Tubular Breast Carcinoma: Large Retrospective Study and Meta-Analysis. *Front Oncol*. 2021 Apr 29;11.
87. Rabinovich I, de Noronha L, Sebastião APM, Lima RS, Urban CA, Schunemann E, et al. HER2-expressing breast tumors are associated with breast cancer stem-cell phenotype CD44 + /CD24 -. *J Bras Patol Med Lab*. 2018 Sep 1;54(5):310–8.
88. Pan H, Wang H, Qian M, Mao X, Shi G, Ma G, et al. Comparison of Survival Outcomes among Patients with Breast Cancer with Distant vs Ipsilateral Supraclavicular Lymph Node Metastases. *JAMA Netw Open*. 2021 Mar 16;4(3).
89. Min Y, Liu X, Hu D, Chen H, Chen J, Xiang K, et al. Risk Factors, Prognostic Factors, and Nomogram for Distant Metastasis in Breast Cancer Patients Without Lymph Node Metastasis. *Front Endocrinol (Lausanne)*. 2021 Nov 24;12.
90. Karakolevska-Ilova M, Zdravkovska M, Jasar D, Petrussevska G, Simeonovska-Joveva E. Can estrogen receptor, progesterone receptor, and proliferative index be considered as isolated prognostic factors of overall survival in early luminal breast cancer? *Open Access Maced J Med Sci*. 2021 Dec 26;9:1313–22.
91. Yazdani A, Haghghat S. Determining Prognostic Factors of Disease-Free Survival in Breast Cancer Using Censored Quantile Regression. *BreastCancer*



(Auckl). 2022;16.



92. Moosdorff M, Vugts G, Maaskant-Braat AJG, Strobbe LJA, Voogd AC, Smidt ML, et al. Contralateral lymph node recurrence in breast cancer: Regional event rather than distant metastatic disease. A systematic review of the literature. *European Journal of Surgical Oncology*. 2015 Sep 1;41(9):1128–36.
93. Onishi K, Watanuki R, Yokoe T, Iwatani T, Yamauchi C, Onishi T. A Case of Brachial Lymph Node Recurrences after the Resection of Locally Advanced Breast Cancer. *Case Rep Oncol*. 2022 Aug 30;15(2):738–44.
94. Bitencourt A, Rossi Saccarelli C, Morris EA, Flynn J, Zhang Z, Khan A, et al. Regional Lymph Node Involvement among Patients with de Novo Metastatic Breast Cancer. *JAMA Netw Open*. 2020 Oct 1;3(10).
95. Ge I, Erbes T, Juhasz-Böss I. Prognostic value and management of regional lymph nodes in locoregional breast cancer recurrence: a systematic review of the literature. *Arch Gynecol Obstet*. 2022 Oct 1;306(4):943–57.